Companies Get Yet More Time To Assess Nitrosamine Risk In EU
Deadline For Assessing Chemical Medicines Extended Until 31 March 2021
After EU regulators decided that biological medicines should be reviewed for the presence of possible nitrosamine impurities – as is already required for chemical medicines – new deadlines have been agreed on to give companies enough time to comply.
